Please assess the completion status of the following clinical trial:

Trial Title: Assessing the Effect of Met DR on Plasma Glucose and PK in Subjects With T2DM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 to 70 (inclusive) years old at Visit 1 (Screening)~2. Was diagnosed with type 2 diabetes mellitus with~   * HbA1c between 6.0 to 9.5% (inclusive) for subjects managing their diabetes with:~     i. Diet and exercise alone, or ii. A stable regimen (minimum of 2 months at Visit 1) of metformin alone, or iii. A stable regimen (minimum of 2 months at Visit 1) of DPP-4 inhibitor alone OR~  * HbA1c between 6.0 to 8.5% (inclusive) for subjects managing their diabetes with a stable (minimum of 2 months at Visit 1) combination regimen of metformin and DPP-4 inhibitors~3. Had normal renal function with an estimated glomerular filtration rate (eGFR) ≥90 mL/min/1.73 m\^2 based on the Modification of Diet in Renal Disease (MDRD) equation~4. Body mass index (BMI) of 25.0 to 40.0 kg/m\^2 (inclusive) at Screening~5. Male, or if female and met all of the following criteria:~   * Not breastfeeding~  * Negative pregnancy test result (human chorionic gonadotropin, beta subunit) at Visit 1 (Screening) (not applicable to hysterectomized females)~  * Surgically sterile, postmenopausal, or if of childbearing potential, practiced and was willing to continue to practice appropriate birth control during the entire duration of the study~6. Had a physical examination with no clinically significant abnormalities as judged by the investigator~7. Ability to understand and willingness to adhere to protocol requirements~8. If on chronic thyroid pharmacologic therapy, the dose must have been stable for at least 3 months prior to Visit 1 (Screening), and must have thyroid-stimulating hormone (TSH) test result in normal range at Visit 1 (Screening)~Exclusion Criteria:~1. Had a clinically significant medical condition that could potentially affect study participation and/or personal well-being, as judged by the investigator, including but not limited to the following conditions:~   * Hepatic disease~  * Renal disease~  * Gastrointestinal disease~  * Endocrine disorder except diabetes~  * Cardiovascular disease~  * Central nervous system diseases~  * Psychiatric or neurological disorders~  * Organ transplantation~  * Chronic or acute infection~  * Orthostatic hypotension, fainting spells or blackouts~  * Allergy or hypersensitivity~2. Had any chronic disease requiring medication that was adjusted in the past 90 days (subjects could take acute intermittent over-the-counter medications such as Tylenol, if needed)~3. Had any drug treatment that affects gastric pH (prescription or over-the-counter), including any antacids or medications such as Rolaids or Pepcid within 2 days of Visit 1 (Screening)~4. Had major surgery of any kind within 6 months of Visit 1 (Screening)~5. Had received a blood transfusion within 6 months of Visit 1 (Screening)~6. Had a history of \>5 kg weight change within 3 months of Visit 1 (Screening)~7. Had clinical laboratory test (clinical chemistry, hematology, or urinalysis) abnormalities other than those expected in subjects with type 2 diabetes and judged by the investigator to be clinically significant at Visit 1 (Screening)~8. Had a physical, psychological, or historical finding that, in the investigator's opinion, would make the subject unsuitable for the study~9. Abused drugs or alcohol or had a history of abuse that in the investigator's opinion would cause the individual to be noncompliant with study procedures~10. Had donated blood within 3 months of the date of the first dose of randomized study medication, or was planning to donate blood during the study~11. Used insulin within 3 months of Visit 1 (Screening)~12. Had received GLP-1 receptor agonists and/or thiazolidinedione treatment within 6 months of Visit 1 (Screening)~13. Had known intolerance to metformin~14. Had received any investigational drug within 2 months (or five half-lives of the investigational drug, whichever was greater) of Visit 1 (Screening)~15. Had known allergies or hypersensitivity to any component of study treatment~16. Was employed by Elcelyx Therapeutics, Inc. (that is an employee, temporary contract worker, or designee of the company)~17. Smoked more than 10 cigarettes per day, 3 cigars per day, 3 pipes per day, used more than 1 can of smokeless tobacco per week, or used a combination of tobacco products that approximate nicotine doses equivalent to 10 cigarettes per day

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 500 mg Met DR BID (Type: ACTIVE_COMPARATOR): Two doses of 500 mg metformin delayed-release
- 1000 mg Met DR qAM (Type: EXPERIMENTAL): One dose of 1000 mg metformin delayed-release in the morning
- 1000 mg Met DR qPM (Type: EXPERIMENTAL): One dose of 1000 mg metformin delayed-release in the evening

Based on this trial design, predict the completion outcome and termination type (if applicable).